News - Par Pharmaceutical, Santarus


Popular Filters

Par Pharmaceutical to acquire JHP Pharmaceutical


US privately-held Par Pharmaceutical has entered into a definitive agreement to acquire JHP Group Holdings,…

GenericsJHP PharmaceuticalsMergers & AcquisitionsPar Pharmaceutical

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus


Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common…

DiabetesGastro-intestinalsGlumetzaMergers & AcquisitionsPharmaceuticalRare diseasesRuconestSalix PharmaceuticalsSantarus

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta


US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Horizon Pharma in Duexis patent settlement


Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

US FDA accepts Ruconest filing from Santarus and Pharming


US drugmaker Santarus (Nasdaq: SNTS) and Netherlands-based Pharming Group (NYSE Euronext: PHARM) say…

BiotechnologyCardio-vascularNorth AmericaPharmingRare diseasesRegulationRuconestSantarus

Pharming and Santarus file BLA for Ruconest with US FDA


Netherlands-based Pharming Group (NYSE Euronext: PHARM) and US licensee Santarus (Nasdaq: SNTS) have…

North AmericaPharmaceuticalPharmingRare diseasesRegulationRuconestSantarus

Par Pharma agrees $45 million settlement over off-label Megace ES promotion


US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Pharming gets $10 million milestone from Santarus on Ruconest progress


Loss-making Dutch biotech company Pharming Group NV (NYSE Euronext: PHARM) said yesterday that, following…

BiotechnologyFinancialPharmingRare diseasesResearchRuconestSantarus

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld


US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Mylan settles litigation with Somaxon relating to its generic Silenor


US generic drugmaker Mylan (Nasdaq: MYL) and its subsidiary, Mylan Pharmaceuticals have entered into…

LegalMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSilenorSomaxon Pharmaceuticals

TPG to acquire Par Pharma for $1.9 billion


Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals,…

GenericsMergers & AcquisitionsPar PharmaceuticalTPG

FDA decides Teva is sole first-to-file on Provigil; Mylan argues ruling


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) said on April 5 that the US Food and Drug…

CephalonGenericsLegalModafinilMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalProvigilRegulationTeva Pharmaceutical Industries

Horizon Pharma sues Par for infringing Duexis patent


Horizon Pharma (Nasdaq: HZNP) has filed a patent infringement lawsuit in the US District Court for the…

DuexisGenericsHorizon PharmaLegalNeurologicalNorth AmericaPar PharmaceuticalPatents

NovaDel regains rights for ondansetron oral spray product


New Jersey, USA-based NovaDel Pharma (OTCBB: NVDL) has announced the termination of certain license agreements…

BioAlliance PharmaLicensingNovaDel PharmaOncologyondansetronPar PharmaceuticalPharmaceuticalTalon Therapeutics

Promotions at Par Pharma as firm grows with acquisitions


US generics drugmaker Par Pharmaceutical (NYSE: PRX) has promoted Thomas Haughey to the role of president…

GenericsManagementPar Pharmaceutical

Santarus and Depomed expand US deal on Glumetza


US drugmakers Santarus (Nasdaq: SNTS) and Depomed (Nasdaq: DEPO) have entered into a new commercialization…

DepomedDiabetesGlumetzaLicensingNorth AmericaPharmaceuticalSantarus

Par Pharma to buy Indian generics group Edict for $37.6 million plus debt


US generics and niche drug company Par Pharmaceutical (NYSE: PRX) has entered into a definitive agreement…

Asia-PacificEdict PharmaceuticalsGenericsMergers & AcquisitionsPar Pharmaceutical

Company Spotlight



Back to top